Abbott Laboratories (BUE:ABT) Other Current Payables: ARS1,538,070 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BUE:ABT Abbott Laboratories BUE:ABT
67 GF Score
Price ARS34,740.00
GF Value ARS50,883.71
Valuation Significantly Undervalued
! 1 Warning Sign
View Full Analysis

What is Abbott Laboratories Other Current Payables?

Abbott Laboratories BUE:ABT +0.12% 67 Other Current Payables is ARS1,538,070 Mil as of Mar. 2026. GuruFocus rates BUE:ABT with a GF Score™ of 67/100 and a GF Value™ of ARS50,883.71 (Significantly Undervalued). The stock has 1 warning sign investors should review.

Abbott Laboratories's Other Current Payables for the quarter that ended in Mar. 2026 was ARS1,538,070 Mil.

Abbott Laboratories's quarterly Other Current Payables increased from Sep. 2025 (ARS1,398,753 Mil) to Dec. 2025 (ARS2,582,199 Mil) but then declined from Dec. 2025 (ARS2,582,199 Mil) to Mar. 2026 (ARS1,538,070 Mil).

Abbott Laboratories's annual Other Current Payables increased from Dec. 2023 (ARS579,405 Mil) to Dec. 2024 (ARS1,661,450 Mil) and increased from Dec. 2024 (ARS1,661,450 Mil) to Dec. 2025 (ARS2,582,199 Mil).

Abbott Laboratories Other Current Payables Related Terms

Abbott Laboratories Other Current Payables Historical Data

* Premium members only.

The historical data trend for Abbott Laboratories's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Abbott Laboratories Other Current Payables Chart

Abbott Laboratories Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Payables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 120,683.05 255,666.24 579,405.00 1,661,450.02 2,582,198.91

Abbott Laboratories Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Payables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,100,150.12 1,222,850.20 1,398,752.77 2,582,198.91 1,538,069.60
BUE:ABT
67GF Score
Abbott Laboratories BUE:ABT
Other Current Payables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Abbott Laboratories Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

Frequently Asked Questions Learn more about Other Current Payables →
What does a Other Current Payables of ARS1,538,070 Mil mean?
Abbott Laboratories (BUE:ABT) has a Other Current Payables of ARS1,538,070 Mil as of Mar. 2026. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Abbott Laboratories and its competitors.
Is Abbott Laboratories' Other Current Payables too high?
Abbott Laboratories' current Other Current Payables is ARS1,538,070 Mil. Overall, Abbott Laboratories has a GF Score™ of 67/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Abbott Laboratories' Other Current Payables compare to SYK and MDT?
Abbott Laboratories' Other Current Payables of ARS1,538,070 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Payables for a Medical Devices & Instruments company?
A good Other Current Payables depends on the Medical Devices & Instruments industry context. However, Other Current Payables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Payables mean?
A high Other Current Payables can signal that a stock is expensive relative to its fundamentals. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Abbott Laboratories and its competitors. Abbott Laboratories's current Other Current Payables is ARS1,538,070 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abbott Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Abbott Laboratories (BUE:ABT) is currently considered Significantly Undervalued. The stock's GF Value™ is ARS50,883.71, compared to a current price of ARS34,740.00 — trading 31.7% below its estimated fair value. The current Other Current Payables is ARS1,538,070 Mil. Abbott Laboratories' overall GF Score™ is 67/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Payables calculated?
Other Current Payables is calculated from a company's financial statements. For Abbott Laboratories (BUE:ABT), the current Other Current Payables is ARS1,538,070 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Abbott Laboratories (BUE:ABT) Overvalued in 2026?

Based on GuruFocus' analysis, Abbott Laboratories stock appears to be undervalued. The current stock price of ARS34,740.00 is trading 31.7% below its estimated GF Value™ of ARS50,883.71. GuruFocus considers Abbott Laboratories to be Significantly Undervalued.

Key valuation signals for BUE:ABT:

  • Other Current Payables: ARS1,538,070 Mil
  • GF Value™: ARS50,883.71 vs. price of ARS34,740.00 (31.7% below fair value)
  • GF Score™: 67/100 with 1 warning sign

No single metric tells the full story. See the BUE:ABT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Abbott Laboratories Business Description

Address 100 Abbott Park Road, Abbott Park, IL, USA, 60064-6400
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.
67GF Score

Get the complete analysis for BUE:ABT

Other Current Payables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

ARS34,740.00
Price
ARS50,883.71
GF Value